Interleukin-12 and tumour necrosis factor-alpha equilibrium is a prerequisite for clinical course free from late complications in children with type 1 diabetes mellitus

Scandinavian Journal of Immunology
Katarzyna ZorenaKrystyna Raczyńska

Abstract

The objective of the study was to analyse levels of IL-12 and TNF-alpha and relate the findings to the occurrence of microangiopathy in children with type 1 diabetes mellitus (DM). We examined a group of 123 children with type 1 DM. Serum levels of IL-12 and TNF-alpha were measured by an immunoenzymatic ELISA technique. TNF-alpha and IL-12 tended to be simultaneously present or absent in the sera of 50% of the children who had not developed complications, thus indicating a state of cytokine's equilibrium. Among the patients with an established retinopathy, two IL-12/TNF-alpha combinations were visible. Either a lack of detectable TNF-alpha was accompanied by measurable IL-12 serum concentrations or TNF-alpha incidence was associated with undetectable IL-12 values. Simultaneous lack of TNF-alpha and presence of IL-12 was associated with a better prognosis as these patients had a significantly lower albumin excretion rate. The state of equilibrium between TNF-alpha and IL-12 is beneficial in patients at early stages of the disease, prior to the occurrence of complications. Shifting the equilibrium towards TNF-alpha seems to promote late complications. It may suggest that a disharmony between pro- and anti-angiogenic function of t...Continue Reading

References

Apr 19, 1995·Journal of the National Cancer Institute·E E VoestJ Folkman
Oct 31, 1996·Annals of the New York Academy of Sciences·A L AngiolilloG Tosato
Dec 11, 1999·Archives of Surgery·M McCourtH P Redmond
Mar 10, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M StraslyF Bussolino
Mar 20, 2002·Cytokine & Growth Factor Reviews·Mario P Colombo, Giorgio Trinchieri
Oct 3, 2002·Nature Reviews. Cancer·Robert Kerbel, Judah Folkman
Jan 1, 2003·The American Journal of Pathology·Michael S GeeWilliam M F Lee
Oct 28, 2003·Diabetes Care·Saul GenuthUNKNOWN Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
Feb 22, 2005·Current Drug Targets. Inflammation and Allergy·Antonella Naldini, Fabio Carraro
Jul 21, 2007·Mediators of Inflammation·Katarzyna ZorenaKrystyna Raczyńska

❮ Previous
Next ❯

Citations

Jan 10, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Antonela Gverović AntunicaVelibor Puzović
Aug 6, 2008·Pediatric Research·Małgorzata MyśliwiecPiotr Wiśniewski
Dec 7, 2013·Mediators of Inflammation·Katarzyna ZorenaKrystyna Raczyńska
Apr 29, 2015·Journal of Diabetes Research·Anna V ZetterqvistMaria F Gomez
Nov 30, 2013·Mediators of Inflammation·Snježana KaštelanSpomenka Ljubić
Aug 25, 2007·Diabetes Research and Clinical Practice·Małgorzata MyśliwiecKrystyna Raczyńska
Jul 26, 2017·International Ophthalmology·Maha E HoussenMohamed E Shaker
Jan 29, 2019·Acta Ophthalmologica·Faryan TayyariChristopher Hudson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.